Affymax N.V. deal

The collaboration initially will target atherosclerosis, central nervous system disorders and women's health diseases such as osteoporosis, breast cancer and endometriosis.

Wyeth-Ayerst will make $47 million in R&D payments over five years and purchase $10 million of newly issued AFMXF common stock at $20 per share. AFMXF has 15.9 million shares outstanding after the purchase. ...